

FDA/EMA APPROVED TARGETED THERAPIES, BASED ON NCCN/ESMO GUIDELINES

NCCN/ESMO guideline-recommended targeted therapies, and approved targeted therapies for other indications are also available.

	COLORECTAL	NSCLC	PROSTATE	BREAST	PANCREATIC	OVARIAN
BRCA1			Olaparib, Rucaparib	Olaparib, Talazoparib (germline)	Olaparib	Olaparib, Rucaparib, Niraparib
CDK12			Olaparib			
EGFR		Afatinib, Dacomitinib, Erlotinib, Gefitinib, Osimertinib, Ramucirumab (+Erlotinib)				
NTRK1/2/3	Larotrectinib, Entrectinib (all solid tumors)					
ROS1		Crizotinib, Entrectinib				
MSI-High	Pembrolizumab, Nivolumab, Ipilimumab	Pembrolizumab (all solid tumors)				
TMB-High	Pembrolizumab (all solid tumors)					

The above table, produced in October 2023, includes a selection of available therapies and should be used for guidance only. NCCN, ESMO, and ASCO guideline-recommended targeted therapies, and approved targeted therapies for other indications are also available. For the latest information on approved targeted therapies, please visit the relevant websites.

CASE STUDY

A 70-year-old male was diagnosed with stage III laryngeal squamous cell carcinoma, a rare type of cancer

Due to the low incidence rate of this cancer, a larger panel which includes an extensive number of genes and genomic biomarkers is more valuable for the patient, as it increases his chances of identifying an actionable mutation and beneficial treatment.

Pan-Cancer Plus identified a **high TMB score of 16mut/Mb** as the only therapy associated biomarker.

ForeSENTIA results led to:

- **Pembrolizumab**, a tumor-agnostic **FDA-approved** immunotherapy drug indicated for high TMB scores, being administered to the patient
- Identification of **2 clinical trials** related to Pembrolizumab

Identification of **3 genetic alterations** that are associated with:

- **7 clinical trials**
- **2 FDA/EMA approved therapies** for other indications

ABOUT MEDICOVER GENETICS

Medicover Genetics is a leading healthcare company specialising in genetic medicine, with more than 25 years of experience in genetics diagnostics. Medicover Genetics offers genetic testing services and genetic counselling, proprietary CE-IVD marked solutions and a versatile Technology Transfer Platform which enables partners to perform high fidelity genetic tests in-house. With services in over 30 countries across Europe, Asia, and Africa, the company empowers laboratories, healthcare professionals and patients to place genetics at the core of medical decisions. Committed to enhancing health and well-being, Medicover Genetics provides meaningful, actionable diagnostic solutions, improving disease prognosis, clinical management, and therapy selection for genetic disorders. The CAP-accredited, CLIA-, GMP- and ISO9001, 15189, and 13485 certified laboratories ensure the highest quality standards. www.medicover-genetics.com

Medicover Genetics is part of Medicover, a leading international healthcare and diagnostic services company founded in 1995 and listed on Nasdaq Stockholm. www.medicover.com




Medicover Genetics Ltd
www.medicover-genetics.com
info.genetics@medicover.com



MKT-ONC-FS-PANS-DR-EN-V03

ForeSENTIA[®]
 tumor profile

Genes, genetic alterations and genomic biomarkers



MEDICOVER
 GENETICS

